Bortezomib in Treating Patients With Unresectable Locally Advanced or

Status Completed

Clinical Trial Summary

This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the objective response rate in patients with unresectable locally advanced or metastatic adenocarcinoma of the bile duct or gallbladder treated with bortezomib.

SECONDARY OBJECTIVES:

I. Determine the time to disease progression in patients treated with this drug.

II. Determine the overall survival of patients treated with this drug. III. Correlate the degree of proteasome inhibition in peripheral blood with degree of proteasome inhibition in tumor specimens of patients treated with this drug.

IV. Correlate phenotypic expression of NF-kB, p53, and other molecular markers in biliary washings and tumor biopsies with clinical outcomes in patients treated with this drug.

V. Correlate treatment with this drug with changes in phenotypic expression of molecular markers in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Adenocarcinoma
Adenocarcinoma of the Extrahepatic Bile Duct
Adenocarcinoma of the Gallbladder
Advanced Adult Primary Liver Cancer
Bile Duct Neoplasms
Cholangiocarcinoma
Gallbladder Neoplasms
Gastrointestinal Cancer
Gastrointestinal Neoplasms
Liver Neoplasms
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer

Clinical Trial Details

NCT number	NCT00085410
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	January 2004

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Not yet recruiting	`NCT05044312` - Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis	N/A
Active, not recruiting	`NCT05053191` - Advancing Nursing Practices in Hospital Oncology Care	N/A
Completed	`NCT03611309` - Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members	N/A
Recruiting	`NCT03602677` - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage	N/A
Recruiting	`NCT03190941` - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Phase 1/Phase 2
Withdrawn	`NCT04030624` - Remote Electronic Patient Monitoring in Gastrointestinal Cancer	N/A
Completed	`NCT02222259` - A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients	N/A
Completed	`NCT02140593` - The Laparotomy Study	Phase 4
Active, not recruiting	`NCT00716209` - Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers	N/A
Recruiting	`NCT01484444` - Biomarker Analysis of Gastrointestinal Cancer	N/A
Completed	`NCT02130427` - A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy	N/A
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00094965` - Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function	Phase 2
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Recruiting	`NCT05226221` - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Recruiting	`NCT03286348` - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer	N/A
Active, not recruiting	`NCT03207594` - Improving Evidence-Based Care for Cancer Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms